Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Osteopenia
Interventions: Tai Chi, Standard Care; Other
Lead sponsor: Harvard University Faculty of Medicine; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Creatine Monohydrate; Drug
Lead sponsor: The Avicena Group; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 8
States / cities: San Francisco, California • Kansas City, Kansas • Albuquerque, New Mexico + 5 more

Conditions: Immunoglobulin A (IgA) Nephropathy
Interventions: Felzartamab, Placebo; Drug · Other
Lead sponsor: HI-Bio, A Biogen Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Oxnard, California • Vacaville, California • Rochester, Minnesota + 1 more

Conditions: Hyperhidrosis
Interventions: Ulthera System Treatment, Sham treatment; Drug
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Healthy Subjects
Interventions: PF-06865571, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Major Depressive Disorder
Interventions: apimostinel, Placebo; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rogers, Arkansas

Conditions: Type 2 Diabetes Mellitus, Renal Impairment
Interventions: LX4211, LX4211 Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 6
States / cities: Anniston, Alabama • Chula Vista, California • Edgewater, Florida + 3 more

Conditions: Tension-Type Headache
Interventions: TNX-201, Placebo; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: San Jose, California • DeLand, Florida • Stockbridge, Georgia + 7 more

Conditions: Tourette Syndrome
Interventions: TEV-50717, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 33
States / cities: Dothan, Alabama • Rogers, Arkansas • Anaheim, California + 27 more

Conditions: Head Lice
Interventions: Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate, Saline 0.9%, Placebo; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Caries,Dental
Interventions: Self-determination theory; Behavioral
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 45 Years
Enrollment: 1,268 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Anamosa, Iowa • Belle Plaine, Iowa • Cedar Rapids, Iowa + 11 more

Conditions: Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
Interventions: Capsaicin Patch; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 8
States / cities: Phoenix, Arizona • Tucson, Arizona • Naples, Florida + 5 more

Conditions: Tobacco Use Disorder
Interventions: Tolcapone, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Substance-Related Disorders
Interventions: Letters; Other
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Enrollment: 851 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Acute Pancreatitis (AP), Gallstone Pancreatitis, Alcoholic Pancreatitis, Trauma Acute Pancreatitis, Hypertriglyceridemia Acute Pancreatitis, Idiopathic (Unknown) Acute Pancreatitis, Medication Induced Acute Pancreatitis, Cancer Acute Pancreatitis, Miscellaneous (i.e. Acute on Chronic Pancreatitis)
Interventions: Pentoxifylline, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
Interventions: Gemcitabine Delivered by Transarterial Microperfusion; Combination Product
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Perfectionism
Interventions: Exposure-Based Treatment for Perfectionism, Stress Management; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Healthy, College Students, Diet Interventions, Vegan Diet, Feasibility Pilot Study, Diet Quality, Lipid Profile, Depressive Symptoms
Interventions: Interactive intervention group, Lecture-based intervention; Other
Lead sponsor: Appalachian State University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Boone, North Carolina

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma (PN)
Interventions: Selumetinib, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Gainesville, Florida • Rockville, Maryland • St Louis, Missouri + 1 more

Conditions: Jaw, Edentulous, Partially
Interventions: Straumann Bone Level Implant; Device
Lead sponsor: Institut Straumann AG; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 2
States / cities: Boca Raton, Florida • Gainesville, Florida

Conditions: Systemic Lupus Erythematosus
Interventions: DZP, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 16 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 63
States / cities: Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 55 more

Conditions: C-Reactive Protein
Interventions: LY5625573, Midazolam, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Los Alamitos, California • Dallas, Texas

Conditions: Atopic Dermatitis
Interventions: 0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Melville, New York

Conditions: Autonomic Nerve Block
Interventions: Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine, Pecto-intercostal Fascial Block with normal saline; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Tai Chi for Osteopenic Women

Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Feasibility Study: Safety and Efficacy of the Ulthera® System for Treatment of Axillary Hyperhidrosis

A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion

Birth to Three - Cavity Free

Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain

Neural Substrates in Nicotine Withdrawal

Behavioral Insights to Encourage Judicious Prescribing of Opioids

Pentoxifylline Treatment in Acute Pancreatitis (AP)

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

A Randomized Controlled Trial of an Exposure-Based Treatment for Perfectionism

Testing the Feasibility and Impact of a Whole-Food Plant-Based Diet Intervention on College Students

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

Clinical Study Comparing Submerged Versus Trans-mucosal Healing of P.004 Implants in the Anterior Mandible and Maxilla

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

Sternotomy PIFB Block in Open Heart Surgery